During August, the total number of short positions held on AlloVir, Inc. went down by a sizeable amount (NASDAQ: ALVR). As of August 31, 5,190,000 shares were borrowed, a 19.8% decline from the number borrowed the day before, which was 4,160,000 shares. The current days-to-cover ratio is 8.6 days; this number was determined based on an average daily volume of trading shares of 485,900.
The most recent quarterly results for AlloVir (NASDAQ: ALVR) were made available to investors on Thursday, August 4. Accordingly, these results were made public.
The announcement made by the company stated that the earnings per share for the quarter came in at $0.69, which is $0.04 more than the average prediction of $0.73. In other words, the earnings per share exceeded expectations by $0.04. As a result, AlloVir is expected to announce a loss of -2.29 cents per share for the current fiscal year, as this is the opinion held by most financial experts.
Beek According to other recent developments, Jeroen B. Van, an insider of AlloVir, sold 15,590 shares on August 16. It was established that each share was sold at an average price of $8.30, which led to a total selling volume of $129,397.00. The price at which the shares were sold was determined. After the completion of the transaction, the corporate insider is now the owner of 386,363 shares of the firm, which have a combined value of $3,206,812.90. The Securities and Exchange Commission (SEC) kept a legal file accessible online and contained the information about the transaction. This information can be viewed. An insider at AlloVir named Beek Jeroen B. Van sold 15,590 shares of the company’s stock, as was mentioned in earlier reports about AlloVir. It was discovered that each share was sold at an average price of $8.30, which led to a total selling volume of $129,397.00. The price at which each share was sold was calculated.
After the completion of the transaction, the corporate insider is now the owner of 386,363 shares of the firm, which have a combined value of $3,206,812.90. Follow the link that was provided in the preceding sentence. You can access the transaction report presented to the Securities and Exchange Commission.
Additionally, on August 18, Chief Executive Officer Diana Brainard sold 4,564 shares of the company’s stock. As a result of the sale of the shares at an average price of $7.76 per share, the total transaction value for the shares was determined to be $35,416.64. As a direct consequence of the transaction, the Chief Executive Officer now has direct control over 637,548 shares of the company. These shares have a combined value of $4,947,372.48. Disclosures that are related to the sale might be found in this section of the website. Insiders of the company sold a total of 25,813 shares of stock and generated revenue of $194,804 during the preceding three months. 54.22% of the company shares are owned by people who work for the company.
When the market opened on Friday, the price of a share of ALVR was $8.16 per transaction. The company’s moving average prices for the previous fifty days are $6.80, and the moving average prices for the past two hundred days are $5.86. During the previous year, the price of AlloVir ranged from a low of $3.17 to a high of $26.41 at various points.
Recently, certain institutional investors and hedge funds made adjustments to the holdings they had previously held in the stock. These adjustments were made in response to recent market events. During the second quarter, Goldman Sachs Group Inc. brought the total amount of AlloVir stock it owned to a level that was 111.5% more than it had been previously. Goldman Sachs Group Inc. has 228,667 shares of the company’s stock, which are currently worth a combined total of $892,000. This comes after an extra 120,563 shares were purchased throughout the quarter. In addition, Jane Street Group LLC grew its shares in AlloVir by 202.6% during the second quarter. After acquiring an additional 20,786 shares during the most recent quarter, Jane Street Group LLC now owns 31,046 shares of the company’s stock, which is $121,000. This brings the total number of shares directly owned by the firm to 31,046.
During the second quarter, Price T. Rowe Associates Inc. MD achieved a rise of 84.2% in the ownership stake it had in AlloVir. As a result of the purchase of an additional 23,136 shares throughout the relevant period, Price T. Rowe Associates Inc. MD now holds a total of 50,611 shares of the company’s stock. These shares have a value of $197,000 and give the firm market capitalization. During the second quarter, Prudential Financial Inc. contributed approximately $66,000 in cash to AlloVir as part of new investment in the company. Corton Capital Inc. strengthened its holdings in AlloVir by increasing the shares it owned during the second quarter by making additional purchases of almost $41,000. Currently, 38.73% of the company’s shares are owned by hedge funds and other institutional investors.
Various research companies have recently shown interest in ALVR due to its promising potential. Morgan Stanley lowered their target price for AlloVir shares from $32.00 to $27.00 in a research report made available to the public on Friday, September 9. Despite this change, they kept an “overweight” rating on the stock. On July 28, SVB Leerink gave the company an “outperform” rating and dropped their price objective for AlloVir from $30.00 to $23.00. In addition to that, they provided the business with an “outperform” rating.